ライフサイエンスコーパス: Chk1 kinase

1 Chk1 kinase inhibitors are currently under clinical inve

2 lay only briefly in CPT medium by activating Chk1 kinase, cdc2.1w cells bypass Chk1 to enter an exten

3 The active Chk1 kinase was essential for both the accurate focal co

4 46d, with potent enzymatic activity against Chk1 kinase.

5 inding interactions between compound 46b and Chk1 kinase, revealed by X-ray cocrystal structure, were

6 gamma-H2AX, replication protein A foci, and Chk1 kinase phosphorylation, a readout for activation of

7 examined the respective roles of the ATR and Chk1 kinases in ovarian cancer cells using genetic and p

8 n abrogates IR-induced activation of ATR and Chk1 kinases, as well as phosphorylation of Cdc2-Tyr15,

9 RS response (RSR) is coordinated by ATR and Chk1 kinases.

10 licon initiation is dependent on the ATR and Chk1 kinases.

11 giectecia-mutated and Rad3-related (ATR) and Chk1 kinases and inhibition of Cdc2/Cyclin B activity.

12 elements in the signaling network (Myt1 and Chk1 kinases), and fits a large and diverse body of data

13 (ataxia telangiectasia and Rad3 related) and Chk1 kinases.

14 t activation involves activation of Wee1 and Chk1 kinases and inhibition of Cdc25A and Cdc25C phospha

15 Cdc25C expression and activation of Wee1 and Chk1 kinases.

16 site previously identified for Chk2 (or/and Chk1) kinase.

17 Although the ATR-Chk1 kinase cascade was associated with hypoxia-induced

18 transmit DNA damage signals through the ATR-Chk1 kinase cascade, whether post-translational modifica

19 473 can be phosphorylated by ATM-Chk2 or ATR-Chk1 kinases.

20 This upregulation requires ATM/ATR/Chk1 kinases.

21 One is the previously characterized Chk1 kinase.

22 SUMOylation occurs in cells with compromised Chk1 kinase activity, necessary for known posttranslatio

23 rgeted phospho-Ser 345, leading to decreased Chk1 kinase activity.

24 system in which the phosphorylation of human Chk1 kinase by ATR (ataxia telangiectasia mutated and Ra

25 A resolution crystal structures of the human Chk1 kinase domain and its binary complex with an ATP an

26 Structural studies of the human Chk1 kinase domain show an open conformation; the activi

27 nserved C-terminal region negatively impacts Chk1 kinase activity.

28 These phenotypes reflect defects in Chk1 kinase induction, as the mutants are either partial

29 rest was also associated with an increase in Chk1 kinase activity.

30 ive indolocarbazole inhibitor (SB-218078) of Chk1 kinase activity and used this compound to assess ce

31 Activation of Chk1 kinase also requires its association with Claspin,

32 is suggests the expression and activation of Chk1 kinase is associated with cells undergoing active D

33 Here, we report that inhibition of Chk1 kinase activity paradoxically leads to the accumula

34 in solution, which results in inhibition of Chk1 kinase activity.

35 Inhibition of Chk1 kinase with 7-hydroxystaurosporine (UCN-01) abrogat

36 An inhibitor of Chk1 kinase activity, UCN-01, overcomes the HuCdc6 media

37 lues of 3-10 nM) and selective inhibitors of Chk1 kinase was described.

38 excision repair leads to phosphorylation of Chk1 kinase in both G1 and S phase of the cell cycle, su

39 might serve as substrates for hCds1/Chk2 or Chk1 kinase activity.

40 s a homolog of the Schizosaccharomyces pombe Chk1 kinase, provides a cell-cycle checkpoint that delay

41 Separately purified Chk1 kinase and KA1 domains are intimately associated in

42 In other systems, Chk1 kinase phosphorylates and suppresses the activity o

43 Here, we show that Chk1 kinase activity is rapidly stimulated in a cell-cyc

44 The Chk1 kinase is a major effector of S phase checkpoint si

45 The Chk1 kinase, an effector of the DNA-damage checkpoint, p

46 w that BRCA1 is essential for activating the Chk1 kinase that regulates DNA damage-induced G2/M arres

47 o demonstrate that serine 83 of Mcd1 and the Chk1 kinase are critical determinants for DSB-induced co

48 ved in the structures between UCN-01 and the Chk1 kinase domain.

49 se TMZ-induced effects were inhibited by the Chk1 kinase inhibitor UCN-01.

50 Taken together our results identify the Chk1 kinase and the Cdc25C pathway as potential targets

51 role of Cdc2 tyrosine phosphorylation in the Chk1 kinase-mediated DNA damage checkpoint has remained

52 partner ATR-interacting protein but not the Chk1 kinase.

53 ivation typically leads to activation of the Chk1 kinase among other substrates.

54 cation checkpoint and phosphorylation of the Chk1 kinase are dependent on RNA primer synthesis by DNA

55 tion specifically destroys regulation of the Chk1 kinase but not the Chk2 kinase, suggesting involvem

56 , we determined the crystal structure of the Chk1 kinase domain in complex with UCN-01.

57 The addition of the Chk1 kinase inhibitor 7-hydroxystaurosporine (UCN-01) to

58 14/Y15 and activating phosphorylation of the Chk1 kinase no longer occur.

59 dine and pyrrolopyrimidine inhibitors of the Chk1 kinase, an oncology target.

60 is intimately linked to the integrity of the Chk1 kinase-Cdc25A phosphatase pathway.

61 TM and ATR kinase inhibitor caffeine, or the Chk1 kinase inhibitor UCN-01.

62 In Schizosaccharomyces pombe, the Chk1 kinase is essential for mitotic arrest and is phosp

63 ve in DNA replication initiation require the Chk1 kinase.

64 he Chk1 catalytic cleft were consistent with Chk1 kinase assays defining substrate suitability.